OP018 Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a deficient commensal bacteria implicated in Crohn's disease

Quévrain, Elodie; Maubert, Marie-Anne; Chain, Florian; Marquant, Rodrigue; Kharrat, Pascale; Carlier, Ludovic; Bermúdez, Laura Cristina Camargo; Pigneur, Bénédicte; Lequin, Olivier; Bridonneau, Chantal; Thomas, G.; Lavielle, Solange; Grill, Jean-Pierre; Chassaing, Gérard; Masliah, J.; Trugnan, Germain; Xavier, Ramnik J.; Langella, Philippe; Sokol, Harry; Seksik, Philippe

doi:10.1016/s1873-9946(14)60019-2

Cited by 33 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…F prausnitzii , R inulinivorans , and R intestinalis are the leading contributors to Starch degradation V in both two cohorts, and they were higher in control than in patient samples. F prausnitzii is an anti‐inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease 68,69 . It is an acetate‐consuming and butyrate‐producing gut microbe has attracted great interest because of its potentially important role in promoting gut health 70 .…”

Section: Discussionmentioning

confidence: 99%

“…It is an acetate‐consuming and butyrate‐producing gut microbe has attracted great interest because of its potentially important role in promoting gut health 70 . A 15 kDa protein produced by F prausnitzii is able to inhibit the NF‐κB pathway in intestinal epithelial cells and to prevent colitis in an animal model 69 . Roseburia and F prausnitzii were identified as highly discriminant for type 2 diabetes 71 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross‐cohort microbial signatures and potential therapeutic target

et al. 2020

View full text Add to dashboard Cite

The gut microbiota is associated with cardiovascular diseases, including atherosclerosis. However, the composition, functional capacity, and metabolites of the gut microbiome about atherosclerosis have not been comprehensively studied. Here, we reanalyzed 25 metagenomic stool samples from Sweden and 385 metagenomic stool samples from China using HUMAnN2, PanPhlAn, and MelonnPan to obtain more sufficient information. We found that the samples from atherosclerotic patients in both cohorts were depleted in Bacteroides xylanisolvens, Odoribacter splanchnicus, Eubacterium eligens, Roseburia inulinivorans, and Roseburia intestinalis. At the functional level, healthy metagenomes were both enriched in pathways of starch degradation V, glycolysis III (from glucose), CDP-diacylglycerol biosynthesis, and folate transformations. R inulinivorans and R intestinalis are major contributors to starch degradation V, while E eligens greatly contribute to the pathway CDPdiacylglycerol biosynthesis, and B xylanisolvens and B uniformis contribute to folate transformations II. The 11 marker species selected from the Chinese cohort distinguish patients from controls with an area under the receiver operating characteristics curve (AUC) of 0.86. Strain-level microbial analysis revealed a geographically associated adaptation of the strains from E eligens, B uniformis, and E coli. Two gut microbial metabolites, nicotinic acid and hydrocinnamic acid, had significantly higher predicted abundance in the control samples compared to the patients in the Chinese cohort, and interestingly nicotinic acid is already an effective lipid-lowering drug to reducing cardiovascular risk. Our results indicate intestinal bacteria such as B xylanisolvens, E eligens, and R inulinivorans could be promising probiotics and potential therapeutic target for atherosclerosis. K E Y W O R D S atherosclerosis, cardiovascular diseases, gut microbiota, metabolites, metagenome | 14167 LIU et aL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross‐cohort microbial signatures and potential therapeutic target

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some studies found that the colonization of F. prausnitzii requires B. thetaiotaomicron and Escherichia coli (E. coli) to be preexisted in the intestine, which could prepare suitable conditions for F. prausnitzii by reducing redox potential and altering the composition of nutrients [32,33]. In addition, F. prausnitzii and normal intestinal microecology can effectively prevent the proliferation of intestinal pathogenic bacteria such as Escherichia coli, Clostridium, and Shigella, which reduce the possibility of intestinal epithelium injury, thereby avoiding the activation of intestinal immune cells and the release of inflammatory factors [34]. erefore, F. prausnitzii is a probiotic with an important protective effect on the human intestine and its reduction will lead to weakened intestinal anti-inflammatory and immune regulation capabilities.…”

Section: The Bionomics Of F Prausnitziimentioning

confidence: 99%

Faecalibacterium prausnitzii: A Next-Generation Probiotic in Gut Disease Improvement

Zhao

2021

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

The researchers are paying more attention to the role of gut commensal bacteria in health development beyond the classical pathogens. It has been widely demonstrated that dysbiosis, which means the alternations of the gut microbial structure, is closely associated with development of intestinal chronic inflammation-related diseases such as inflammatory bowel disease (IBD), and even infectious diseases including bacterial and viral infection. Thus, for reshaping ecological balance, a growing body of the literatures have proposed numerous strategies to modulate the structure of the gut microbiota, which provide more revelation for amelioration of these inflammation or infection-related diseases. While the ameliorative effects of traditional probiotics seem negligeable, emerging next generation probiotics (NGPs) start to receive great attention as new preventive and therapeutic tools. Encouragingly, within the last decade, the intestinal symbiotic bacterium Faecalibacterium prausnitzii has emerged as the “sentinel of the gut,” with multifunction of anti-inflammation, gut barrier enhancement, and butyrate production. A lower abundance of F. prausnitzii has been shown in IBD, Clostridium difficile infection (CDI), and virus infection such as COVID-19. It is reported that intervention with higher richness of F. prausnitzii through dietary modulation, fecal microbiota transplantation, or culture strategy can protect the mice or the subjects from inflammatory diseases. Therefore, F. prausnitzii may have potential ability to reduce microbial translocation and inflammation, preventing occurrences of gastrointestinal comorbidities especially in COVID-19 patients.

show abstract

“…Studies using clinical cohorts have revealed several molecular features that are associated with disease heterogeneity. These include genetic (18,19) microbial (20), and metabolic factors (10,21). The appreciation of the wide range of individual factors influencing the pathology of CIDs intensified research endeavours to further tailor treatment strategies to the patient's molecular characteristics (22,23).…”

Section: Introductionmentioning

confidence: 99%

Precision Nutrition in Chronic Inflammation

et al. 2020

View full text Add to dashboard Cite

The molecular foundation of chronic inflammatory diseases (CIDs) can differ markedly between individuals. As our understanding of the biochemical mechanisms underlying individual disease manifestations and progressions expands, new strategies to adjust treatments to the patient’s characteristics will continue to profoundly transform clinical practice. Nutrition has long been recognized as an important determinant of inflammatory disease phenotypes and treatment response. Yet empirical work demonstrating the therapeutic effectiveness of patient-tailored nutrition remains scarce. This is mainly due to the challenges presented by long-term effects of nutrition, variations in inter-individual gastrointestinal microbiota, the multiplicity of human metabolic pathways potentially affected by food ingredients, nutrition behavior, and the complexity of food composition. Historically, these challenges have been addressed in both human studies and experimental model laboratory studies primarily by using individual nutrition data collection in tandem with large-scale biomolecular data acquisition (e.g. genomics, metabolomics, etc.). This review highlights recent findings in the field of precision nutrition and their potential implications for the development of personalized treatment strategies for CIDs. It emphasizes the importance of computational approaches to integrate nutritional information into multi-omics data analysis and to predict which molecular mechanisms may explain how nutrients intersect with disease pathways. We conclude that recent findings point towards the unexhausted potential of nutrition as part of personalized medicine in chronic inflammation.

show abstract

OP018 Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a deficient commensal bacteria implicated in Crohn's disease

Cited by 33 publications

References 0 publications

Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross‐cohort microbial signatures and potential therapeutic target

Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross‐cohort microbial signatures and potential therapeutic target

Faecalibacterium prausnitzii: A Next-Generation Probiotic in Gut Disease Improvement

Precision Nutrition in Chronic Inflammation

Contact Info

Product

Resources

About